Key result
Infliximab therapy is linked to the development of segmental vitiligo in rheumatoid arthritis.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
The tumor necrosis factor alpha is a cytokine related to immune and inflammatory processes by acting on different parts of the body. It is secreted by several cell types including macrophages, lymphocytes, monocytes, neutrophils, dendritic cells, among others. Infliximab is a chimeric monoclonal antibody that specifically binds to soluble and transmembrane tumor necrosis factor alpha form blocking its action. In rheumatoid arthritis it is used because the cytokines that cause inflammation in this disease are regulated by tumor necrosis factor alpha and IL-1. We report the case of a 46-year-old patient with rheumatoid arthritis who developed segmental vitiligo after two months using infliximab. The event aims to alert to the existence of this adverse effect that can be induced with the use of this medication.
No takes yet. Share an insight, caveat, or question.
Carvalho et al. (2014) conducted a case report in Rheumatoid arthritis and segmental vitiligo (n=1). Infliximab was evaluated on Development of segmental vitiligo. Infliximab use for 2 months was associated with the development of segmental vitiligo in 1 patient (46 years old) with rheumatoid arthritis.
Synapse has enriched 10 related papers. Consider them for comparative context: